Reviva Pharmaceuticals Holdings, Inc. (RVPH)
RVPH moved a median of -0.81% 30 minutes after news, and -1.21% by the close. How RVPH actually reacts to news — the realized, point-in-time move the market made, measured across 237 labeled events over the last three years with zero look-ahead.
RVPH’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.12% | 39% | 236 |
| 30-min | -0.81% | 42% | 237 |
| 60-min | -0.94% | 42% | 237 |
| to close | -1.21% | 40% | 237 |
| Middle 50% of RVPH reactions | -4.00% to +1.21% |
|---|---|
| Median reaction (30-min) | -0.81% |
| Measured reactions | 237 |
Half of all Reviva Pharmaceuticals Holdings, Inc. news events land between -4.00% and +1.21% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RVPH reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | +0.69% | 73% | -1.87% |
| Rating reiterations | 56 | -0.25% | 46% | +0.52% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how RVPH ranks against every other measured name →
That’s how RVPH usually reacts — get an email when it moves on news →Email me when RVPH moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RVPH's baseline. Nothing else.
Recent RVPH events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference | Press release | GlobeNewswire | +0.00% | +7.75% | |
| Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +3.58% | +9.54% | |
| Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th | Press release | GlobeNewswire | -1.15% | -0.43% | |
| Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase | Press release | GlobeNewswire | +6.21% | +27.33% | |
| Form 10-Q REVIVA PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -8.79% | +8.88% | |
| Form 8-K REVIVA PHARMACEUTICALS For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -8.33% | -2.19% | |
| Form 8-K REVIVA PHARMACEUTICALS For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -8.79% | +8.88% | |
| Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -8.79% | +8.88% | |
| Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications | Press release | GlobeNewswire | +0.00% | -3.34% | |
| Form 8-K REVIVA PHARMACEUTICALS For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | -0.57% | -0.54% | |
| Reviva Announces Letter to Shareholders | Press release | GlobeNewswire | -0.57% | -0.54% | |
| Form 10-K REVIVA PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.39% | -12.55% | |
| Form 8-K REVIVA PHARMACEUTICALS For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +1.39% | -12.55% | |
| Form S-8 REVIVA PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | +1.39% | -12.55% | |
| Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +1.39% | -12.55% | |
| Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering | Press release | GlobeNewswire | +5.05% | +9.48% | |
| Form 8-K REVIVA PHARMACEUTICALS For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | +3.36% | -4.95% | |
| Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering | Press release | GlobeNewswire | -23.33% | -7.40% | |
| Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering | Press release | GlobeNewswire | -23.33% | -7.40% | |
| Form 8-K REVIVA PHARMACEUTICALS For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | -10.04% | |
| Form 8-K REVIVA PHARMACEUTICALS For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | -1.53% | -7.82% | |
| Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia | Press release | GlobeNewswire | +2.67% | +2.75% | |
| Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum | Press release | GlobeNewswire | +5.26% | -9.60% | |
| Form 8-K REVIVA PHARMACEUTICALS For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | -2.19% | +3.65% | |
| Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia | Press release | GlobeNewswire | -2.19% | +3.65% | |
| Form DEFA14A REVIVA PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +1.16% | +0.32% | |
| Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025 | Press release | GlobeNewswire | -0.34% | +3.45% | |
| Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis | Press release | GlobeNewswire | +4.00% | +6.00% | |
| Form ARS REVIVA PHARMACEUTICALS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.36% | +5.40% | |
| Form DEF 14A REVIVA PHARMACEUTICALS For: Dec 18 | SEC filing · Form DEF | SEC EDGAR | +0.36% | +5.40% | |
| Form DEFA14A REVIVA PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +0.36% | +5.40% | |
| Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference | Press release | GlobeNewswire | +1.58% | +1.96% | |
| Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025 | Press release | GlobeNewswire | +1.69% | -0.47% | |
| Form PRE 14A REVIVA PHARMACEUTICALS For: Dec 18 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -1.40% | |
| Form 8-K REVIVA PHARMACEUTICALS For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +1.88% | -5.02% | |
| Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners | Press release | GlobeNewswire | -9.41% | -12.11% | |
| Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference | Press release | GlobeNewswire | -0.28% | +26.31% | |
| Form 8-K REVIVA PHARMACEUTICALS For: Sep 26 | SEC filing · Form 8-K | SEC EDGAR | +0.07% | +2.80% | |
| Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference | Press release | GlobeNewswire | +1.77% | -7.72% | |
| Form 8-K REVIVA PHARMACEUTICALS For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | -1.79% | +9.75% | |
| Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering | Press release | GlobeNewswire | -1.25% | +0.60% | |
| Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering | Press release | GlobeNewswire | -1.25% | +0.60% | |
| Form 10-Q REVIVA PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.02% | +10.20% | |
| Form 8-K REVIVA PHARMACEUTICALS For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -0.02% | +10.20% | |
| Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -0.02% | +10.20% | |
| Form 8-K REVIVA PHARMACEUTICALS For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -2.10% | -12.36% | |
| Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering | Press release | GlobeNewswire | -5.79% | -19.70% | |
| Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering | Press release | GlobeNewswire | -5.79% | -19.70% | |
| Form 8-K REVIVA PHARMACEUTICALS For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.98% | |
| Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference | Press release | GlobeNewswire | -0.10% | -3.27% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RVPH section they belong to.
Where else RVPH is measured.
RVPH earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Reviva Pharmaceuticals Holdings, Inc.'s median reaction calculated?
Every labeled RVPH news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 237 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of RVPH's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RVPH's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.